Actively Recruiting
Advancing Non-Abstinence Outcomes in the Treatment of Methamphetamine Use Disorder
Led by William Stoops · Updated on 2026-06-08
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
W
William Stoops
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying methamphetamine use disorder to evaluate the benefits of reducing drug use rather than complete abstinence. This research aims to fill a critical gap by showing how lowering methamphetamine use can improve physical, psychological, and social health. The findings may help change current treatment goals and speed up the development of new therapies for methamphetamine use disorder. Participants are randomly assigned to one of two groups. One group receives payments for providing urine samples, while the other group receives payments specifically for methamphetamine-negative urine samples as part of a behavioral approach called Contingency Management. The study lasts for 12 weeks of intervention, followed by a 12-week post-intervention follow-up period to monitor outcomes. During the study, participants will have their mean arterial pressure and endothelin-1 levels measured at various points, including baseline and several weeks into participation. Sleep quality is also assessed at baseline and during follow-up visits. Researchers will collect these data to understand the biopsychosocial effects of reduced methamphetamine use. Participants commit to regular visits and assessments throughout the 24-week total study duration.
CONDITIONS
Brief Title
Non-Abstinence Outcomes in Methamphetamine Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be age 18 years or older
- Self-report methamphetamine use in the week before screening
- Provide a methamphetamine-positive urine sample at screening
- Meet DSM-5 criteria for moderate to severe Methamphetamine Use Disorder
- Be seeking treatment for methamphetamine use
- Be able and willing to commit to the 12-week intervention and 12-week follow-up
- Individuals stable on buprenorphine or methadone for Opioid Use Disorder may participate
You will not qualify if you...
- Current or past medical or psychiatric illness that interferes with participation, such as dependence on other drugs requiring detox, unstable heart conditions, compromised immune function, or severe other substance use disorders
- Poor venous access preventing blood draws
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants receive a behavioral intervention involving contingency management where they are rewarded for providing methamphetamine negative urine samples during the 12-week intervention period.
Weekly visits for up to 12 weeks
Duration - 12 weeks
Participants are monitored for an additional 12 weeks after the intervention to assess ongoing outcomes.
Visits at Week 4, Week 8, and Week 12 of follow-up
Trial Site Locations
Total: 1 location
1
Psychopharmacology of Addiction Laboratory
Lexington, Kentucky, United States, 40507
Actively Recruiting
Research Team
W
William W Stoops, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here